🔗 Share this article

While the US continues making sweeping changes to its vaccination recommendations, an unexpected name appears unexpectedly: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines during the pandemic and has concentrated on alleged deaths after COVID-19 immunization in her brief position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders had intended to reveal radical revisions to the childhood vaccine schedule in December, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would place the US at odds with a large portion of the international standard with little proof for benefit. The planned update has been delayed until the new year.

In place of Vinay Prasad, Høeg is set to speak at the event. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this year.

A New Direction at the Regulatory Body

This interim role could signify a closer partnership between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood immunization guidelines in the US to become more like the Danish model, a nation with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

To date comments, she has kept her attention on immunizations – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Høeg has no apparent track record in medication creation, approval processes or administrative roles, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in industry regulation.”

Past heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, said Janet Woodcock. “Frankly, she lacks the kind of background that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“Many people just focuses on the novel medication approvals, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and all of those have to be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant leadership element to the job, which supervises more than 5,000 employees. “It’s a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Programs

Regarding concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among FDA leaders on immunizations, a representative responded that the “questions stem from flawed presumptions”.

“This background aligns with the functions of her position,” the representative stated, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg takes over the agency head's new fast-track approval initiative, a disputed rapid drug-approval program that apparently troubled her preceding directors. “How are these drugs being chosen for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of confidentiality occurring at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards more relaxed regulations of all drugs, aside from shots.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if concerning, past, some experts observe. She released a research paper using unverified crowd-sourced reports to determine the incidence of myocarditis after Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current administration featured changing regulations for new vaccines and ending “non-essential” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has reportedly suggested preventing teenage boys from receiving COVID-19 vaccinations.

“She’s an complete ideologue who begins with her preconceived notions and reverse-engineers to accommodate the science in a extremely misleading, untruthful fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|